Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 260 Paclitaxel 216 Cyclophosphamide 173 Docetaxel 146 Letrozole 126 Fulvestrant 121 Capecitabine 121 Doxorubicin 111 Carboplatin 98 Bevacizumab 90 exemestane 88 Anastrozole 85 Tamoxifen 77 Lapatinib 77 pembrolizumab 68 Albumin-Bound Paclitaxel 67 pertuzumab 62 palbociclib 60 Taxes 59 Gemcitabine 57 eribulin 48 130-nm albumin-bound paclitaxel 47 Radiotherapy 46 Everolimus 44 Ado-Trastuzumab Emtansine 43 Vinorelbine 39 ixabepilone 32 Epirubicin 30 Cisplatin 30 pegfilgrastim 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × elacestrant × Breast × Clear all

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡